New combo shows promise for Hard-to-Treat colorectal cancer
NCT ID NCT04963283
First seen Feb 11, 2026 · Last updated Jun 20, 2026 · Updated 20 times
Summary
This phase 2 trial is testing a combination of two drugs, cabozantinib and nivolumab, in 48 people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if the combination can shrink or stabilize tumors. All participants have a type of colorectal cancer called microsatellite stable (MSS), which typically does not respond well to immunotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCHealth Family Medicine - Greeley
Greeley, Colorado, 80634, United States
-
UCHealth Harmony Campus
Fort Collins, Colorado, 80528, United States
-
UCHealth Medical Center of the Rockies
Loveland, Colorado, 80538, United States
-
UCHealth Memorial Hospital Central
Colorado Springs, Colorado, 80909, United States
-
University of Colorado Hospital
Aurora, Colorado, 80012, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cabozantinib and nivolumab
What this could lead to
If successful, this combination could offer a new treatment option to control advanced MSS colorectal cancer when other therapies have failed.
What could go wrong
This is a small, early-phase trial with only 48 participants. The combination may not work better than existing options and could cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.